Drug Search Results

Vantictumab

Alternative Names: vantictumab
Latest Update: 2020-11-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: FZD10 Antagonist

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Mereo BioPharma
Company Location: LONDON X0 W1G0QF
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Vantictumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Small Cell Lung Cancer|Pancreatic Cancer|Breast Cancer|Non-Small-Cell Lung Cancer

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
18R5-003	P1	Completed	Pancreatic Cancer	2017-10-01	41%
18R5-002	P1	Completed	Breast Cancer	2017-06-01	41%
18R5-004	P1	Completed	Non-Small-Cell Lung Cancer\|Small Cell Lung Cancer	2016-12-01	41%

Recent News Events

Date	Type	Title
11/01/2020	PubMed	Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer.
06/01/2020	PubMed	A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions